Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EPS (Weighted Average and Diluted) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$2.28 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 19.72% to -$2.28 in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.4, a 109.87% decrease, with the full-year FY2024 number at $112.62, up 649.9% from a year prior.
  • EPS (Weighted Average and Diluted) was -$2.28 for Q3 2025 at Inhibrx Biosciences, down from -$1.85 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $128.52 in Q2 2024 to a low of -$7.81 in Q4 2023.
  • A 3-year average of $9.2 and a median of -$3.58 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 3081.9% in 2024, then crashed 101.44% in 2025.
  • Inhibrx Biosciences' EPS (Weighted Average and Diluted) stood at -$7.81 in 2023, then soared by 42.73% to -$4.47 in 2024, then surged by 48.99% to -$2.28 in 2025.
  • Per Business Quant, the three most recent readings for INBX's EPS (Weighted Average and Diluted) are -$2.28 (Q3 2025), -$1.85 (Q2 2025), and -$2.8 (Q1 2025).